The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions. - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer. - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent. - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised. - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
Cytoskeletal associated protein tyrosine phosphatase
Phosphatase with ezrin domain
Protein tyrosine phosphatase non receptor type 14
Protein tyrosine phosphatase pez
Protein-tyrosine phosphatase pez
Tyrosine protein phosphatase non receptor type 14
Tyrosine-protein phosphatase non-receptor type 14
FunctionProtein tyrosine phosphatase which may play a role in the regulation of lymphangiogenesis.
Tissue specificityExpressed in a variety of human tissues including kidney, skeletal muscle, lung and placenta.
Involvement in diseaseDefects in PTPN14 are a cause of choanal atresia and lymphedema (CHATLY) [MIM:613611]. A disease characterized by posterior choanal atresia and lymphedema. Additional features are a high-arched palate, hypoplastic nipples, and mild pectus excavatum. Note=A homozygous deletion in PTPN14 predicted to result in frameshift and premature truncation, has been shown to be the cause of choanal atresia and lymphedema in one family.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Non-receptor class subfamily. Contains 1 FERM domain. Contains 1 tyrosine-protein phosphatase domain.
Post-translational modificationsPhosphorylated upon DNA damage, probably by ATM or ATR.